Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans
WEINZ, C, SCHWARZ, T, KUBITZA, D, MUECK, W, LANG, D
Published in Drug metabolism and disposition (01.05.2009)
Published in Drug metabolism and disposition (01.05.2009)
Get full text
Journal Article
Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers
Levi, M., Moore, K. T., Castillejos, C. F., Kubitza, D., Berkowitz, S. D., Goldhaber, S. Z., Raghoebar, M., Patel, M. R., Weitz, J. I., Levy, J. H.
Published in Journal of thrombosis and haemostasis (01.09.2014)
Published in Journal of thrombosis and haemostasis (01.09.2014)
Get full text
Journal Article
Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study
Kreutz, R., Persson, P. B., Kubitza, D., Thelen, K., Heitmeier, S., Schwers, S., Becka, M., Hemmrich, M.
Published in Journal of thrombosis and haemostasis (01.10.2017)
Published in Journal of thrombosis and haemostasis (01.10.2017)
Get full text
Journal Article
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
Kubitza, Dagmar, Becka, Michael, Voith, Barbara, Zuehlsdorf, Michael, Wensing, Georg
Published in Clinical pharmacology and therapeutics (01.10.2005)
Published in Clinical pharmacology and therapeutics (01.10.2005)
Get more information
Journal Article
First‐in‐man–proof of concept study with molidustat: a novel selective oral HIF‐prolyl hydroxylase inhibitor for the treatment of renal anaemia
Böttcher, M., Lentini, S., Arens, E. R., Kaiser, A., Mey, D., Thuss, U., Kubitza, D., Wensing, G.
Published in British journal of clinical pharmacology (01.07.2018)
Published in British journal of clinical pharmacology (01.07.2018)
Get full text
Journal Article
Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects
Mueck, W, Becka, M, Kubitza, D, Voith, B, Zuehlsdorf, M
Published in International journal of clinical pharmacology and therapeutics (01.06.2007)
Published in International journal of clinical pharmacology and therapeutics (01.06.2007)
Get more information
Journal Article
Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis
Stass, H., Rink, A. D., Delesen, H., Kubitza, D., Vestweber, K.-H.
Published in Journal of antimicrobial chemotherapy (01.09.2006)
Published in Journal of antimicrobial chemotherapy (01.09.2006)
Get full text
Journal Article
Pharmacokinetics of moxifloxacin, a novel 8‐methoxy‐quinolone, in patients with renal dysfunction
Stass, H., Kubitza, D., Halabi, A., Delesen, H.
Published in British journal of clinical pharmacology (01.03.2002)
Published in British journal of clinical pharmacology (01.03.2002)
Get full text
Journal Article
The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction
Stass, H., Bührmann, S., Mitchell, A., Kubitza, D., Möller, J.‐G., Kribben, A., Wenzel, R. R., Schäfers, R. F.
Published in British journal of clinical pharmacology (01.12.2007)
Published in British journal of clinical pharmacology (01.12.2007)
Get full text
Journal Article
Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin
Kubitza, Dagmar, Becka, Michael, Mueck, Wolfgang, Zuehlsdorf, Michael
Published in Journal of clinical pharmacology (01.09.2006)
Published in Journal of clinical pharmacology (01.09.2006)
Get more information
Journal Article